Motivational Enhancement to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the therapeutic usefulness of incorporating Motivational Enhancement Treatment into the standard drug abuse treatment entry process of Community Treatment Programs on improving treatment engagement, retention, and outcome.
| Condition | Intervention | Phase |
|---|---|---|
|
Substance-Related Disorders |
Behavioral: Behavior Therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Primary Purpose: Treatment |
| Official Title: | Motivational Enhancement Treatment (MET) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse |
- Drug use
- Retention
- HIV risk behaviors
- Psychosocial functioning
| Estimated Enrollment: | 561 |
| Study Start Date: | May 2001 |
| Study Completion Date: | August 2004 |
| Primary Completion Date: | August 2004 (Final data collection date for primary outcome measure) |
Participants seeking treatment at the participating CTPs will be randomly assigned to either "standard" or "MET/MI" treatment, with a 1- and 3-month follow-up. Primary outcome measures will include (1) treatment retention (e.g., number of sessions/weeks completed, the rate of patients completing 3 or more subsequent sessions, and (2) substance use (e.g., urinalyses, days of opioid, cocaine, marijuana, alcohol use, rates of abstinence). Secondary outcomes will include motivation, psychosocial functioning, HIV risk behaviors, treatment utilization, and patient satisfaction. Process assessments will include measures of the working alliance as well as therapist adherence/competence ratings which will evaluate how effectively MET/MI was implemented. Participating CTPs will implement one of two independent protocols, depending on which is the best suited or feasible for the intake procedures at their clinic. Thus, following an invitation to participate, explanation of the study, and provision of informed consent, patients would complete a brief assessment battery followed by either: 1) Random assignment to 3 individual sessions of standard treatment (treatment as usual) at the program versus 3 individual sessions of MET. or 2) Random assignment to 1 individual standard assessment/evaluation session.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Individuals will be eligible for the protocol who:
- Are seeking outpatient treatment for any substance use disorder
- Are willing to participate in the protocol (e.g., to be randomized to treatment, be contacted for follow-up assessment, to have their sessions audiotaped)
- Are able to understand and provide written informed consent
Exclusion Criteria:
Individuals will be excluded who:
- Are not sufficiently medically or psychiatrically stable to participate in outpatient treatment
- Are seeking detoxification only, methadone maintenance treatment or residential inpatient treatment
Contacts and Locations| United States, California | |
| Haight Ashbury Free Clinics | |
| San Francisco, California, United States, 94117 | |
| Tarzana Treatment Center | |
| Tarzana, California, United States, 91356 | |
| United States, Connecticut | |
| CT Renaissance, Inc. | |
| Norwalk, Connecticut, United States, 06852 | |
| LMG Programs, Inc. | |
| Stamford, Connecticut, United States, 06901 | |
| United States, Pennsylvania | |
| Northeast Treatment Center | |
| Philadelphia, Pennsylvania, United States, 19123 | |
| Rehab After Work | |
| Philadelphia, Pennsylvania, United States, 19103 | |
| Principal Investigator: | Kathleen Carroll, Ph.D. | VA Connecticut Healthcare System |
More Information
Additional Information:
No publications provided
| Responsible Party: | Kathleen Carroll, Ph.D., Yale University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00032981 History of Changes |
| Obsolete Identifiers: | NCT00016770 |
| Other Study ID Numbers: | NIDA-CTN-0004-1 |
| Study First Received: | April 5, 2002 |
| Last Updated: | April 13, 2010 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Substance-Related Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 23, 2013